Indication

Treatment of patients with a body weight of 10kg or above with atypical haemolytic uremic syndrome (aHUS) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.

Medicine details

Medicine name:
ravulizumab (Ultomiris)
SMC ID:
SMC2330
Pharmaceutical company
Alexion Pharma UK Ltd
BNF chapter
Nutrition and blood
Submission type
Full
Publication due date:
Q2 2021
SMC meeting date:
Q2 2021
Patient group submission deadline:
01 February 2021